X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47) 47
oncology (46) 46
5-fluorouracil/folinic acid (44) 44
index medicus (43) 43
1st-line treatment (35) 35
colorectal neoplasms - drug therapy (33) 33
colorectal cancer (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
chemotherapy (27) 27
colorectal neoplasms - pathology (26) 26
capecitabine (24) 24
oxaliplatin (24) 24
cancer (23) 23
cetuximab (22) 22
camptothecin - analogs & derivatives (20) 20
fluorouracil - administration & dosage (20) 20
bevacizumab (18) 18
aged (17) 17
female (17) 17
metastasis (17) 17
middle aged (17) 17
randomized phase-iii (17) 17
fluorouracil (16) 16
fluorouracil - analogs & derivatives (16) 16
male (16) 16
treatment outcome (16) 16
deoxycytidine - analogs & derivatives (15) 15
irinotecan (15) 15
leucovorin (15) 15
leucovorin - administration & dosage (15) 15
adult (14) 14
organoplatinum compounds - administration & dosage (14) 14
antineoplastic agents - therapeutic use (13) 13
liver metastases (13) 13
oral capecitabine (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
camptothecin - administration & dosage (12) 12
care and treatment (12) 12
fluorouracil - adverse effects (12) 12
irinotecan/5-fluorouracil/folinic acid (12) 12
liver neoplasms - secondary (12) 12
deoxycytidine - administration & dosage (11) 11
hematology, oncology and palliative medicine (11) 11
metastatic colorectal cancer (11) 11
neoplasm metastasis (11) 11
drug therapy (10) 10
fluorouracil - therapeutic use (10) 10
fluorouracil plus leucovorin (10) 10
phase-ii trial (10) 10
surgery (10) 10
5-fluorouracil (9) 9
antibodies, monoclonal, humanized (9) 9
clinical trials as topic (9) 9
disease-free survival (9) 9
growth-factor receptor (9) 9
survival rate (9) 9
trial (9) 9
antimitotic agents (8) 8
antineoplastic agents (8) 8
health aspects (8) 8
metastatic colorectal-cancer (8) 8
neoadjuvant chemotherapy (8) 8
panitumumab (8) 8
research (8) 8
adjuvant treatment (7) 7
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
camptothecin - adverse effects (7) 7
camptothecin - therapeutic use (7) 7
carcinoma (7) 7
colorectal neoplasms - mortality (7) 7
combination chemotherapy (7) 7
digestive system diseases (7) 7
final report (7) 7
leucovorin - adverse effects (7) 7
liver neoplasms - drug therapy (7) 7
organoplatinum compounds - therapeutic use (7) 7
oxaliplatin-based chemotherapy (7) 7
animals (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antineoplastic agents - administration & dosage (6) 6
chemotherapy, adjuvant (6) 6
colon-cancer (6) 6
deoxycytidine - adverse effects (6) 6
drug administration schedule (6) 6
gastroenterology & hepatology (6) 6
infusional fluorouracil (6) 6
leucovorin - therapeutic use (6) 6
medicine & public health (6) 6
neoplasm staging (6) 6
organoplatinum compounds - adverse effects (6) 6
plus irinotecan (6) 6
therapy (6) 6
young adult (6) 6
1st-line therapy (5) 5
adjuvant (5) 5
analysis (5) 5
antibodies, monoclonal - administration & dosage (5) 5
cetuximab plus irinotecan (5) 5
combination (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2008, Volume 19, Issue 10, pp. 1720 - 1726
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2012, Volume 23, Issue 5, pp. 1190 - 1197
Background: This multicenter randomized trial compared oral capecitabine with bolus i.v. 5-fluorouracil (5-FU)/folinic acid (FA) as adjuvant therapy for stage... 
5-fluorouracil/folinic acid | Colon cancer | Pharmacodynamic markers | Capecitabine | Elderly | Adjuvant therapy | LEUCOVORIN | colon cancer | elderly | PHASE-III | adjuvant therapy | INFUSION | FLUOROURACIL | BREAST | MONTHLY REGIMEN | capecitabine | ORAL CAPECITABINE | ONCOLOGY | pharmacodynamic markers | CARCINOMA | LEVAMISOLE | Hand-Foot Syndrome - epidemiology | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Prognosis | Age Factors | Follow-Up Studies | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Colonic Neoplasms - metabolism | Young Adult | Deoxycytidine - pharmacokinetics | Hand-Foot Syndrome - diagnosis | Adenocarcinoma - metabolism | Fluorouracil - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Biomarkers, Pharmacological - analysis | Colonic Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Adenocarcinoma - drug therapy | Leucovorin - pharmacokinetics | Pilot Projects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Fluorouracil - pharmacokinetics | Neoplasm Staging | Pharmacokinetics | Biomarkers, Pharmacological - metabolism | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1065 - 1075
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1481 - 1492
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2007, Volume 43, Issue 14, pp. 2037 - 2045
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 2010, Volume 16, Issue 25, pp. 3133 - 3143
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2019, Volume 19
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 1 - 15
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2016, Volume 78, Issue 2, pp. 397 - 403
Journal Article